Sfoglia per AUTORE
CALIFANO C
Collezione ASL Biella

  

Items : 10

End of induction [(18)F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial. in European journal of nuclear medicine and molecular imaging / Eur J Nucl Med Mol Imaging. 2024 Sep;51(11):3311-3321. doi: 10.1007/s00259-024-06765-z. Epub 2024 Ma

2024
ASL Biella
AOU Alessandria

Versari A; Luminari S; Pennese E; Perrone T; Liberati AM; Stefani PM; Ibatici A; Usai SV; Falcinelli F; Vitolo U; Gini G; Roti G; Galimberti S; Musto P; Mannina D; Conconi A; Bari A; Massaia M; Califano C; Chiarenza A; Arcari A; Pavone V; Bianchi B; Bolis SAM; Musuraca G; Tosi P; Barbieri E; Ladetto M; Monaco L; et alii...

IELSG38: phase II trial of front-line chlorambucil plus subcutaneous rituximab induction and maintenance in mucosa-associated lymphoid tissue lymphoma. in Haematologica / Haematologica. 2024 Aug 1;109(8):2564-2573. doi: 10.3324/haematol.2023.283918.

2024
ASL Biella
AOU Alessandria
AOU Città della Salute di Torino

Thieblemont C; Zucca E; Luminari S; Bertoni F; Rossi D; Cavalli F; Pietrantuono G; Re F; Spina M; Landi F; Houot R; Merli M; Liberati AM; Haioun C; Cartron G; Devizzi L; Occhini U; Casasnovas RO; Califano C; Celli M; Pulsoni A; Angrilli F; Conconi A; Tessoulin B; Tilly H; Zanni M; Cabras MG; Capochiani E; Morschhauser F; et alii...

Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi. in Hematological oncology / Hematol Oncol. 2023 Oct;41(4):655-662. doi: 10.1002/hon.3184. Epub 2023 May 28.

2023
AO Cuneo
ASL Biella

Gini G; Federico M; Luminari S; Marcheselli L; Catellani H; Skrypets T; Stefani PM; Pastore D; Pennese E; Liberati AM; Ballerini F; Vitolo U; Usai SV; Capponi M; Galimberti S; Perrone T; Re F; Mannina D; Musto P; Conconi A; Bari A; Massaia M; Ghiggi C; Pulsoni A; Musuraca G; Califano C; Merli M; Manni M; Nizzoli ME; et alii...

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. in American journal of hematology / Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

2023
ASL Città di Torino
ASL Torino 4
AO Cuneo
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria

Santini V; Della Porta MG; Giordano L; Finelli C; Pasini P; Naldi I; Turrini M; Tanasi I; Tosi P; Selleri C; Frigeni M; Sancetta R; Norata M; Grimaldi D; Marchetti M; Galimberti S; Fianchi L; Ferrara F; Bono R; Calvisi A; Castelli A; Di Bona E; Di Veroli A; Nicolino B; Occhini U; Rivoli G; Molteni A; Genua A; Guarini A; et alii...

Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) in Blood

2021
AOU Città della Salute di Torino
ASL Biella

Benevolo G; Ferrero S; Villivà N; Castiglione A; Monaco F; Boccomini C; Cabras MG; Califano C; Casula P; Cavallo F; Conconi A; Drandi D; Gaidano G; Gregorini AI; Felici S; Ferrante M; Mannina D; Molinari AL; Musto P; Musuraca G; Merli M; Sartori R; Tani M; Varettoni M; Vitolo U; Orsucci L;

Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL) in Blood

2021
AOU Città della Salute di Torino
ASL Biella

Luminari S; Nizzoli ME; Chiarenza A; Mannina D; Tucci A; Boccomini C; Farina L; Olivieri J; Marcheselli L; Ferrero S; Arcaini L; Pulsoni A; Musuraca G; Califano C; Merli M; Bari A; Conconi A; Re F; Balzarotti M; Ladetto M; Patti C; Pinto A; Cabras MG; Musto P; Gini G; Arcari A; Manni M; Versari A; Federico M; et alii...

RESPONSE ADAPTED POST INDUCTION THERAPY IN FOLLICULAR LYMPHOMA: UPDATED RESULTS OF THE FOLL12 TRIAL BY THE FONDAZIONE ITALIANA LINFOMI (FIL) in Haematologica

2021
ASL Biella

Luminari S; Galimberti S; Versari A; Tucci A; Boccomini C; Farina L; Zaja F; Marcheselli L; Ferrero S; Arcaini L; Pulsoni A; Musuraca G; Califano C; Merli M; Bari A; Conconi A; Del Giudice I; Re F; Stefani PM; Usai SV; Perrone T; Gini G; Falini B; Gattei V; Manni M; Ladetto M; Mannina D; Federico M;

NEXT GENERATION SEQUENCING PROVIDES NOVEL MOLECULAR MARKERS FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA: BIOLOGICAL RESULTS FROM FONDAZIONE ITALIANA LINFOMI (FIL) FOLL12 TRIAL in Haematologica

2021
ASL Biella

Genuardi E; Ferrero S; Della Starza I; Grassi S; Bomben R; Mantoan B; Drandi D; Dogliotti I; Alessandria B; Ferrante M; Ragaini S; Civita AM; Ghiggi C; Pulsoni A; Ronconi S; Merli M; Califano C; Castellino C; Bari A; Conconi A; De Novi LA; Del Giudice I; Gattei V; Galimberti S; Luminari S; Ladetto M; Federico M;

Clinical and molecular results of the phase II BRB (bendamustine, rituximab and bortezomib) trial of the fondazione italiana linfomi (FIL) for relapsed/refractory waldenström macroglobulinemia patients in Blood

2018
ASL Biella
AOU Città della Salute di Torino

Benevolo G; Ferrero S; Andriani A; Castiglione A; Baraldi A; Boccomini C; Cabras MG; Califano C; Cavallo F; Conconi A; Curreli L; Drandi D; Gaidano G; Felici S; Ferrante M; Mannina D; Merli M; Molinari AL; Musto P; Musuraca G; Rossi FG; Sartori R; Tani M; Varettoni M; Vitolo U; Orsucci L;

IELSG-38: A phase II study of chlorambucil in combination with rituximab followed by maintenance therapy with subcutaneous rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT) in Blood

2017
ASL Biella

Luminari S; Cavalli F; Zucca E; Thieblemont C; Molinari AL; Pulsoni A; Ielmini N; Cabras MG; Capochiani E; Califano C; Tilly H; Salvi F; Conconi A; Palombi F; Cavallo F; Gouill SL; Gini G; Ferrari A; Gyan E; Morschhauser F; Coiffier B; Musuraca G; Guieze R; Marino D; Stathis A; Gregorini A; Gressin R; Orsucci L; Perrot A; et alii...